3rd Feb 2012 16:30
Disclosure and Transparency Rule 5.8.12
Notification of major interest in shares
On 2 February 2012, Investor AB notified the Company that, on 1 February 2012, its interest in the US$0.25 ordinary shares of the Company (the "Shares") had gone above a whole percentage point threshold to 4.02%.
The number of Shares, and voting rights, held by Investor AB remains unchanged at 51,587,810 and the increase in the percentage is due to the decrease in the number of Shares in issue as notified by the Company in its monthly voting rights and capital disclosure on 1 February 2012.
The full notification from Investor AB is set out below.
A C N Kemp
Company Secretary
3 February 2012
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: | AstraZeneca PLC | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | ||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | ||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | ||||
An event changing the breakdown of voting rights | ||||
Other (please specify): | A change in the total voting rights notified by AstraZeneca PLC on 1 February 2012 | P | ||
3. Full name of person(s) subject to thenotification obligation: | Investor AB | |||
4. Full name of shareholder(s) (if different from 3.): | N/A | |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: | 1 February 2012 | |||
6. Date on which issuer notified: | 2 February 2012 | |||
7. Threshold(s) that is/are crossed orreached: | Holding increased to above 4%, from above 3% | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights | ||||||||||||
Direct | Direct | Indirect | Direct | Indirect | ||||||||||||
Ordinary Shares of $0.25 each | 51,587,810 | 51,587,810 | 51,587,810 | 51,587,810 | N/A | 4.02% | N/A | |||||||||
ISIN - GB0009895292 | ||||||||||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate | Exercise/Conversion Period | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
N/A | N/A | N/A | N/A | N/A | ||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date | Exercise/Conversion period | Number of voting rights instrument refers to
| % of voting rights
| |||||||||||
N/A | N/A | N/A | N/A |
N/A | Nominal | Delta | ||||||||||
N/A | N/A | |||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
51,587,810 | 4.02% | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: | ||
N/A | ||
Proxy Voting: | ||
10. Name of the proxy holder: | N/A | |
11. Number of voting rights proxy holder will ceaseto hold: | N/A | |
12. Date on which proxy holder will cease to holdvoting rights: | N/A | |
13. Additional information: | This notification has been prepared using the total voting rights figure of 1,283,229,265 ordinary shares as set out in the public announcement made by AstraZeneca PLC on 1 February 2012 | |
14. Contact name: | Martin Bennett - Assistant Company Secretary | |
15. Contact telephone number: | 020 7604 8157 | |
Related Shares:
Astrazeneca